Neuraxis

NRXS

Market cap $87.9M

CARMEL, Ind., April 22, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced four additional health insurers with medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), representing approximately 1.25 million covered lives. These medical policies expand incremental access to IB-Stim treatment for beneficiaries in West Virginia, New Hampshire, South Carolina, Virginia, and Florida.

CARMEL, Ind., April 10, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced that on April 10, 2026, its Board of Directors declared a dividend on its Series B Preferred Stock.

NRXS witnesses strong revenue growth and expanding coverage in fourth-quarter 2025, but rising costs and commercialization investments weigh on profitability.

NeurAxis, Inc. (NRXS) Q4 2025 Earnings Call Transcript

CARMEL, Ind., March 19, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the fourth quarter period and full year ended December 31, 2025.

NeurAxis posts its fifth straight quarter of double-digit expansion, but rising costs and margin pressure weigh on third-quarter 2025 results.

NeurAxis, Inc. ( NRXS ) Q3 2025 Earnings Call November 11, 2025 9:00 AM EST Company Participants Brian Carrico - President, CEO & Director Timothy Henrichs - Chief Financial Officer Conference Call Participants Ben Shamsian Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the NeurAxis Reports Third Quarter 2025 Financial Results Conference Call.

Conference call will be held today, Tuesday, November 11 at 9:00 am ET Conference call will be held today, Tuesday, November 11 at 9:00 am ET

NRXS reports strong second-quarter 2025 revenue growth and lower losses, but gross margin compression remains a key concern.

NeurAxis, Inc. (NYSE:NRXS ) Q2 2025 Earnings Conference Call August 12, 2025 9:00 AM ET Company Participants Brian Carrico - President, CEO & Director Timothy Robert Henrichs - Chief Financial Officer Conference Call Participants Ben Shamsian - Unidentified Company Chase Richard Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Lindsay Leeds - Unidentified Company Operator Good day, everyone, and welcome to the NeurAxis Report Second Quarter 2025 Financial Results. [Operator Instructions] Please note that this conference is being recorded.